Form 4: Nurix Therapeutics Director, David L. Lacey, Acquires 25,000 Stock Options

David L. Lacey, a director of Nurix Therapeutics, acquired 25,000 stock options on May 19, 2025, exercisable at $9.51.

Summary

• On May 19, 2025, David L. Lacey, a director of Nurix Therapeutics, acquired 25,000 stock options.
• The exercise price of these options is $9.51.
• The options vest 100% on the earlier of the next annual meeting of the Issuer's stockholders or May 19, 2026, subject to continued service.
• The options expire on May 18, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating a director's acquisition of stock options, which is a common practice.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule of the options is tied to the director's continued service and the company's annual meeting.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Option grants are a common form of executive compensation in the biotech industry.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment, as it may signal confidence in the company's future.

Key Dates

Keywords

stock options, director, Nurix Therapeutics, NRIX, acquisition, beneficial ownership, Form 4